Short Interest in PURE Bioscience (OTCMKTS:PURE) Grows By 155.8%

PURE Bioscience (OTCMKTS:PURE) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 26,140 shares, an increase of 155.8% from the November 30th total of 10,219 shares. Based on an average trading volume of 105,877 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the company’s stock are sold short. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 105,877 shares, the short-interest ratio is currently 0.2 days.

PURE Bioscience Trading Up 0.6%

PURE traded up $0.00 during trading on Friday, hitting $0.05. 7,236 shares of the company’s stock traded hands, compared to its average volume of 57,589. The stock has a market capitalization of $5.21 million, a price-to-earnings ratio of -1.55 and a beta of 0.51. PURE Bioscience has a 12-month low of $0.04 and a 12-month high of $0.21. The company’s 50 day simple moving average is $0.06 and its two-hundred day simple moving average is $0.08.

PURE Bioscience (OTCMKTS:PURE) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.01) EPS for the quarter. The company had revenue of $1.71 million during the quarter.

About PURE Bioscience

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.